

Amendments to the Claims

This listing of claims will replace all prior versions, and listings of claims in the application.

1 - 23. (Cancelled)

24. (Withdrawn) A method for producing a ~~specifically attenuated~~ the vaccine of claim 62 ~~wherein the RNase activity residing in glycoprotein E^{RNS} is~~ inactivated.

25. (Withdrawn) The method of claim 24, wherein said RNase activity is inactivated by deletions and/or mutations of at least one amino acid of said glycoprotein.

26. (Withdrawn) The method of claim 25, wherein said deletions and/or mutations are located at the amino acids at position 295 to 307 and/or position 338 to 357, as described in figure 1 for the CSFV Alfort strain in an exemplary manner or corresponding thereto in other strains, of said glycoprotein.

27. (Withdrawn) The method according to claim 26, wherein said RNase activity is inactivated by deletion or mutation of the amino acid at position 346, as described in figure 1 for the CSFV Alfort strain in an exemplary manner or corresponding thereto in other strains, of said glycoprotein.

28. (Withdrawn) The method according to claim 27, wherein said RNase activity is inactivated by the deletion of the histidine residue at position 346, as described in figure 1 for the CSFV Alfort strain in an exemplary manner or corresponding thereto in other strains, of said glycoprotein.

29-61. (Cancelled)

62. (New) A vaccine comprising a BVDV or CSFV pestivirus, wherein the RNase activity of glycoprotein E^{RNS} of said BVDV or CSFV pestivirus is inactivated by a mutation of at least one amino acid of said glycoprotein with the proviso that when said pestivirus is the CSFV pestivirus, the amino acid at position 297 or 346 of SEQ ID NO:34 is not lysine.

63. (New) The vaccine according to claim 62, wherein said vaccine is a live vaccine.

64. (New) The vaccine according to claim 62, wherein said RNase activity of glycoprotein E^{RNS} of said BVDV or CSFV pestivirus is inactivated by a mutation of at least one amino acid in the active site of said glycoprotein.

65. (New) The vaccine according to claim 62, wherein said RNase activity of glycoprotein E^{RNS} of said BVDV or CSFV pestivirus is inactivated by a deletion of at least one amino acid of said glycoprotein.

66. (New) The vaccine according to claim 62, wherein said pestivirus is CSFV.

67. (New) The vaccine according to claim 66, wherein said RNase activity of glycoprotein E^{RNS} of said CSFV is inactivated by a mutation of at least one amino acid located at positions 295 to 357 of SEQ ID NO:34.

68. (New) The vaccine according to claim 66, wherein said RNase activity of glycoprotein E^{RNS} of said CSFV is inactivated by a mutation of at least one amino acid located at positions 338 to 357 of SEQ ID NO:34.

69. (New) The vaccine according to claim 62, wherein said pestivirus is BVDV.

70. (New) The vaccine according to claim 69, wherein said RNase activity of glycoprotein E^{RNS} of said BVDV is inactivated by a deletion of at least one amino acid of said glycoprotein.

71. (New) A vaccine comprising a pestivirus, wherein said RNase activity of glycoprotein E^{RNS} of said pestivirus is inactivated by a mutation of at least one amino acid located in the conserved E^{RNS} sequence SLHGIWPEKIC (SEQ ID NO:7).

72. (New) The vaccine according to claim 71, wherein said vaccine is a live vaccine.

73. (New) The vaccine according to claim 71, wherein said RNase activity of glycoprotein E^{RNS} of said pestivirus is inactivated by a deletion of at least one amino acid located in the conserved E^{RNS} sequence SLHGIWPEKIC (SEQ ID NO:7).

74. (New) The vaccine according to claim 71, wherein said RNase activity of glycoprotein E^{RNS} of said pestivirus is inactivated by a deletion of at least one amino acid of said glycoprotein.

75. (New) The vaccine according to claim 71, wherein said pestivirus is BVDV.

76. (New) The vaccine according to claim 71, wherein said pestivirus is CSFV.

77. (New) A vaccine comprising a pestivirus, wherein said RNase activity of glycoprotein E^{RNS} of said pestivirus is inactivated by a mutation of at least one amino acid located in the conserved E^{RNS} sequence RHEWNKHGWCNW (SEQ ID NO:8).

78. (New) The vaccine according to claim 77, wherein said vaccine is a live vaccine.

79. (New) The vaccine according to claim 77, wherein said RNase activity of glycoprotein E^{RNS} of said pestivirus is inactivated by a deletion of at least one amino acid located in the conserved E^{RNS} sequence RHEWNBKHWGCNW (SEQ ID NO:8).

80. (New) The vaccine according to claim 77, wherein said RNase activity of glycoprotein E^{RNS} of said pestivirus is inactivated by a mutation of the second histidine of the conserved E^{RNS} sequence RHEWNBKHWGCNW (SEQ ID NO:8).

81. (New) The vaccine according to claim 77, wherein said RNase activity of glycoprotein E^{RNS} of said pestivirus is inactivated by a deletion of the second histidine of the conserved E^{RNS} sequence RHEWNBKHWGCNW (SEQ ID NO:8).

82. (New) The vaccine according to claim 77, wherein said pestivirus is CSFV.

83. (New) The vaccine according to claim 77, wherein said pestivirus is BVDV.

84. (New) The vaccine according to claim 79, wherein said pestivirus is CSFV.

85. (New) The vaccine according to claim 85, wherein said pestivirus is BVDV.

86. (New) The vaccine according to claim 81, wherein said pestivirus is CSFV.

87. (New) The vaccine according to claim 81, wherein said pestivirus is BVDV.

88. (New) The vaccine according to claim 86, wherein said CSFV pestivirus is the Alfort strain.

89. (New) The vaccine according to claim 85, wherein said BVDV pestivirus is the BVDV strain cp7.

90. (New) The vaccine according to claim 62 for inducing an immunological response in an animal.

91. (New) The vaccine according to claim 71 for inducing an immunological response in an animal.

92. (New) The vaccine according to claim 77 for inducing an immunological response in an animal.